Roche’s Pirfenidone Bet Validates China Venture
This article was originally published in PharmAsia News
Executive Summary
China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.
You may also be interested in...
Roche Wins InterMune, But For A Price
With the $8.3 billion purchase price, Roche gains InterMune’s sole drug, pirfenidone for idiopathic pulmonary fibrosis, pending at FDA with action expected Nov. 23.
China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.